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A B S T R A C T
Objective of this study was to evaluate the intraocular pressure-reducing effect of
latanoprost as monotherapy after replacing current dual therapy in glaucoma patients.
The 6-months study comprised 189 patients with primary open angle glaucoma who
were treated at least 6 months with two different kind of topical medications ( -blockers,
pilocarpine, dorzolamide and brimonidine). Due to local side effects, multiple dosing re-
gime and inadequately controlled intraocular pressure (IOP), they where switched to
latanoprost 0.005% monotherapy. After switched to latanoprost, mean (IOP) was mea-
sured at baseline, after l5 days, 2 and 6 months of treatment. After six-months 178 pa-
tients had completed the study. These analyses enrolled all patients (n=189), thus, the
Intention-To-Treat (ITT) results were shown instead of the results of the reduced popu-
lation. IOP was clinically importantly reduced from baseline level. Five patients had
uncontrolled IOP. The difference between IOP before (21.9 2.4) and after 15 days
(17.4 1.7), 2 months (16.7 1.8) and 6 months (16.6 1.4) was statistically significant
(p< 0.001). 90% patients has reached target IOP 18 mm. A conjunctival hyperaemia in
18 (9%), stinging and itching in 7 (4%) patients was reported. Increased iris pigmenta-
tion was seen in 3 (2%) patients. The results of this study indicate that dual therapy in
open-angle glaucoma can effectively be replaced by latanoprost monotherapy in many
patients.
Introduction
Latanoprost is a prostaglandin F2 an-
alog and a selective F-prostaglandin re-
ceptor agonist that effectively reduce in-
traocular pressure (IOP) in patients with
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glaucoma1–3. Latanoprost markedly in-
creased uveoscleral outflow4,5. It has been
found that latanoprost does not alter the
aqeous humour production to a clinically
significant extent5. In many patients top-
ical  adrenergic antagonists alone do not
sufficiently lower IOP and additional me-
dications have to be prescribed. Adminis-
tration of several medications may be in-
convenient for the patients6. Switching to
another drug is an alternative in patients
in who two different kind of topical medi-
cations no longer control the IOP suffi-
ciently. A long-term maintance with mo-
notherapy in the management of glau-
coma would therefore be advantageous
for the patients.
The purpose of this study was to eval-
uate the pressure-reducing effect of la-
tanoprost as monotherapy, after replac-
ing current dual therapy ( -blockers, pilo-
carpine, dorsolamide and brimonidine) in
glaucoma patients whose IOP was inade-
quately controlled, over time from base-
line to six months.
Material and Methods
This multicentre study included 189
glaucoma patients from 6 centers in a
6-month open-label comparison of lata-
noprost monotherapy to the current dual
therapy: 132 were on timolol and pilo-
carpin, 43 timolol and dorsolamde and 14
brimonidine and timolol combination. Af-
ter obtaining approval from the appro-
priate regulatory authorities and ethics
commitees, oral consent was obtained
from all patients before entering the stu-
dy. The study protocol followed the guide-
lines of the Declaration of Helsinki.
All participants, aged 51–74 (mean
61.1 13.2 years), enrolled in study were
diagnosed as suffering of primary open-
angle glaucoma, based on having inade-
quately controlled IOP on current local
therapy, open angle on gonioscopy, no evi-
dence of underlying ocular or systemic
cause of high IOP, glaucomatous visual
field defect and papillary excavation (C/D
vertical > 0.3). The patients were inclu-
ded in the study by the judgement of the
investigator based of the disease status of
each individual patient. In addition the
patients should be on therapy with topi-
cal  -adrenergic antagonists in combina-
tion with pilocarpine, brimonidine or dor-
zolamide. Exclusion criteria included any
treatment with more than two glaucoma
medications and any previous treatment
with latanoprost, current use of contact
lenses, previous filtering surgery, argon
laser trabeculoplasty, pregnant women
and any ocular inflammation within
three months were reasons for excluded
from study. The patients were examined
at a prestudy visit within 4 weeks of trial
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Time after commencement of the therapy (months)
Examinations Baseline 0.5 2 6
Gonioscopy X
Visual field X X
Ophthalmoscopy X X X X X
Visual acuity X X X X X
Adverse events X X X X X
Slit-lamp examination X X X X X
Intraocular pressure X X X X X
treatment initiation. Table 1 presents the
schedule of examinations.
Intraocular pressure was measured by
Goldmann applanation tonometer. In each
eye three measurements were performed
and the mean of the three measurements
was used in the statistical analyses. IOP
were recorded at baseline and 15 days, 2
months and 6 months after the initiation
of latanoprost. Examinations were done
at 9 a.m., 1 p.m. and 5 p.m.
Statistical analysis was done. Analy-
sis of variance model was used the IOP
reduction as response, and center as fac-
tor.
The minimal true mean IOP reduction
that the trial was designed to determine
was 4 mmHg with power 90%, 5% signifi-
cance level and it was estimated of the
standard deviation (SD) 1.5 mmHg of the
IOP reduction.
Results
Of the 189 patients enrolled in the
study, 178 had completed the study. Six
patients were lost to follow up. Five pa-
tients had uncontrolled IOP and they un-
derwent on trabeculectomy. In this study
the results were presented as the Inten-
tion-To-Treat (ITT) results based on 189
patients. The missing IOP values were
replaced with the last measurement IOP
value for each patient.
Table 2 shows that there was no clini-
cally important differences in IOP values
between centers.
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TABLE 2
INTRAOCULAR PRESSURE ON EACH MEASUREMENT AT ALL ENROLLED PATIENTS (N=189)
IN 6 CENTERS
Center 1 Center 2 Center 3 Center 4 Center 5 Center 6
Baseline IOP* 22.2 20.1 21.3 22.2 21.9 23.4
Baseline SD 2.4 2.9 2.2 1.2 2.3 2.2
Baseline SEM 0.4 0.6 0.4 0.3 0.4 0.4
Baseline –95% 21.3 18.7 20.4 21.6 20.9 22.6
Baseline +95% 23.0 21.5 22.2 22.7 22.7 24.3
15 days IOP* 17.7 16.3 17.5 17.2 17.3 17.0
15 days SD 1.9 1.5 1.7 1.8 1.5 1.5
15 days SEM 0.3 0.3 0.3 0.3 0.3 0.3
15 days –95% 17.0 15.7 16.9 17.1 16.7 16.5
15 days +95% 18.4 17.1 18.2 18.3 17.8 17.6
2 months IOP* 17.6 15.9 16.6 16.7 16.7 16.4
2 months SD 2.0 2.4 1.5 1.6 1.6 1.4
2 months SEM 0.3 0.5 0.3 0.3 0.3 0.2
2 months –95% 16.9 14.8 16.0 16.2 16.0 15.9
2 months +95% 18.3 17.0 17.2 17.2 17.4 17.0
6 months IOP* 16.5 16.3 16.3 16.7 16.6 16.8
6 months SD 1.5 2.0 1.0 1.4 1.2 1.5
6 months SEM 0.2 0.4 0.2 0.2 0.2 0.3
6 months –95% 16.0 15.4 16.0 16.2 16.2 16.2
6 months +95% 17.0 17.3 16.8 17.1 17.1 17.4
* The mean IOP values in mmHg of three measurements from 9 a.m. to 5 p.m
The mean IOP at each measurement
is presented on Table 3. The results from
Table 2 and Table 3 are presented with
the standard deviation (SD), with the
standard error of the mean (SEM) and
95% confidence interval (CI) at each
treatment duration. At baseline the mean
IOP was 21. 9 2.4 mm Hg. At the end of
the study after 6 months of treatment,
the mean IOP was 16.6 1.4 mmHg.
The pressure-reducing effect of lata-
noprost as monotherapy and comparison
with the results of other studies is pre-
sented on Table 4. The results are pre-
sented with mean IOP values and SEM.
90% patients reached target IOP  18
mmHg (besed on the ITT population).
Adverse ocular events was reported by
15% patients on Table 5.
No systemic adverse event was repor-
ted.
Discussion
Combination of two topical medica-
tions is common in the treatment of glau-
coma. A topical medications that reduces
inflow such as  -adrenergic antagonist or
carbonic anhydrase inhibitors preferably
is combined with medication that increa-
se outflow such as pilocarpine and lata-
noprost. A multidosing regime may be
inconvient for the patients and can result
in poor compliance6. It is a great impor-
tance to consider the option of switching a
patient from dual therapy to monothe-
rapy when the IOP is inadequately con-
trolled. In our study patients with glau-
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TABLE 3





SD SEM –95% +95%
Baseline 21.9 2.4 0.18 21.6 22.3
After 15 days 17.4 1.7 0.13 17.1 17.6
After 2 months 16.7 1.8 0.13 16.5 17.0
After 6 months 16.6 1.4 0.25 15.9 16.9
* The mean IOP values of three measurements from 9 a.m. to 5 p.m.; F=2.7, df=20, p<0.001.
TABLE 4








149 25.2 8.5  0.3 Watson et al. (1995)
89 24.8 8.6  0.4 Alm et al. (1995)
244 25.1 6.2  0.2 Camras et al. (1998)
829 24.8 7.7  0.1 Hedman et al. (2000)
129 21.9 5.3  0.1 Mandi} et al. (2001)
TABLE 5
PERCENTAGE AND NUMBER OF PATIENTS
WITH REPORTED OCULAR ADVERSE EVENTS
(N=189)
Conjunctival hyperemia 18 (9%)
Itching 7 (4%)
Increase iris pigmentation 3 (2%)
coma inadequately controlled on current
dual therapy with topical  adrenergic an-
tagonists in combination with pilocar-
pine, or dorsolamide or brimonidine were
switched to treatment with latanoprost
once daily.
The IOP measured at baseline, after
15 days, 2 months and 6 months, was
considered a relevant point of clinical effi-
cacy for one tratment arm-latanoprost, in
patients who were switched from several
combinations of previous tratment. At six
months 178 patients had completed the
study. The difference between IOP before
and after l5 days, 2 months and 6 months
was significant and 90% patients has rea-
ched target IOP  18 mmHg. This results
show that latanoprost applied topically
once daily is at least effective in reducing
the IOP as the other combinations of topi-
cal medications. Similar results were
founded in other studies1–4,7,8.
No serious side effects were observed.
Mild conjunctival hyperemia was obser-
ved in 16 patients, stinging and itching in
7 patients. Slit lamp examinations re-
vealed increased iris pigmentation in 3
patients.
Glaucoma is a chronic disease and the
effect of the drugs over time is of clinical
interest. With prolonged treatment many
drugs including  -blockers lose some of
their initial effect9,10. Only five patients
had uncontrolled IOP and they under-
went trabeculectomy.
The results of this multicenter study
showed that latanoprost 0.005% applied
topically once daily is effective in reduc-
ing the IOP, and dual therapy in open-an-
gle glaucoma can effectively be replaced
by latanoprost monotherapy in many pa-
tients.
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EVALUACIJA INTRAOKULARNE HIPOTENZIVNE
U^INKOVITOSTI LATANOPROSTA KAO MONOTERAPIJE
KOD GLAUKOMA OTVORENOG KUTA
S A @ E T A K
Cilj rada bio je odrediti u~inak latanoprosta, kao monoterapije kojim je zamijenjena
dvojna terapija, na sni`enje intraokularnog tlaka kod glaukomskih bolesnika. Longi-
tudinalna 6-mjese~na studija uklju~ila je 189 bolesnika sa glaukomom otvorenog kuta.
Svi bolesnici koristili su terapiju dvama lijekovima ( -blokeri, pilokarpin, dorzolamid i
brimonidin) najmanje 6 mjeseci. Zbog lokalnih ne`eljenih popratnih promjena, potrebe
za pre~estim doziranjima, te neodgovaraju}oj kontroli intraokularnog tlaka preba~eni
su na lije~enje jednim lijekom – latanoprostom 0.005%. Po zamjeni terapije mjeren je
intraokularni tlak na dan zamjene, nakon 15 dana, te nakon 2 i 6 mjeseci. Nakon 6
mjeseci 178 bolesnika uspje{no je zavr{ilo studiju. Me|utim, prema terapijskoj namje-
ri (eng. Intention-To-Treat), ovim su analizama prikazani rezultati svih 189 bolesnika
koji su uklju~eni u ispitivanje, a ne njihov reducirani broj. Do{lo je do klini~ki zna-
~ajnog smanjenja intraokularnog tlaka. Pet bolesnika imalo je nekontrolirano visok
intraokularni tlak. Razlika tlaka prije (21.9 2.4), nakon 15 dana (17.4 1.7), nakon 2
mjeseca (16.7+1.8) i nakon 6 mjeseci (16.6 1.4) statisti~ki je zna~ajna (p<0.001). 90%
bolesnika doseglo je takozvani ciljani intraokularni tlak (manji ili jednak 18 mmHg).
Zabilje`ena je konjunktivalna hiperemija kod 18 (9%), te subjektivni simptomi pec-
kanja i bockanja kod 7 (4%) bolesnika. Poja~ana pigmentacija {arenice zabilje`ena je
kod 3 (2%) bolesnika. Rezultati ove studije ukazuju da dvojna terapija mo`e biti uspje-
{no zamijenjena terapijom latanoprostom kao monoterapijom kod mnogih bolesnika sa
glaukomom otvorenog kuta.
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